This report The World Market for Molecular Diagnostics: Potential and Reality, What’s Hot and What’s Not estimates the market for molecular diagnostics and provides a realistic look at the role of molecular testing and its future in various market segments. Kalorama Information’s lead diagnostics analyst Shara Rosen, R.T., MBA, also reviews the competitors in the market and their latest moves.
There have been many predictions made about a molecular revolution in diagnostics. Indeed some are now taking place, while other predictions have not turned out to be true. How can companies sort out what is effective and what is not in this market?
World Market for Molecular Diagnostics: Potential and Reality, What’s Hot and What’s Not provides the insights needed to gain a clear picture of the industry, helping you to make better strategic decisions. It not only contains current market data for business planning but also goes beyond the numbers to fully assess what is going on in the market. For over a decade, Shara Rosen has reviewed the molecular diagnostics market. A lot has changed, and a lot has stayed the same. There is intense competition but also opportunities for entrants in some areas.
What are the important developments in the market? Who are the small innovators in this industry and how are the big players reacting to them? Which developments are “hot” and which trends have not caught on? In this report, Rosen provides answers to these questions.
Far from being a cheerleader of what is clearly a growth market, The World Market for Molecular Diagnostics -Potential and Reality, What’s Hot and What’s Not provides a detailed examination of molecular testing today. Among the data points the report provides are the following:
- Current Market Size and Forecast for Molecular Segments (Infectious Disease, Blood Screening, Histology, Oncology, Prenatal, Coagulation, Tissue Typing, Inherited Diseases, Pharmacodiagnostics and Other)
- Infectious Disease Molecular Sales by Disease (Hepatitis, HIV, GC/Chlamydia, HAI, Respiratory, Organism ID, Mycobacteria/TB, others)
- Revenues of Top Molecular Diagnostic Companies
- Recent Mergers and Acquisitions
- Revenues of Test Service Companies
- Geographic Breakout of the Molecular Diagnostics Market by Region (North America, Europe, Asia, ROW)
- Sample Prep Market, 2010 and 2015
- Breakout of Molecular Histology/Cytology Market (in situ hybridization, HPV, Tissue Microarrays), 2010 and 2015
- Important CLIA Lab Developments, 2008-2010
More and more laboratories offer complex panels of tests that help physicians evaluate disease risk and make therapeutic decisions. Government and private healthcare payers have recognized the value of new molecular tools and have agreed to pay for them.
This renewed interest in IVD in general and more particularly in molecular diagnostics has lead to the commercialization of a number of technological tools that make more sensitive and specific tests possible. Some of these technological innovations include: cost-effective, multiplexed testing platforms coupled with high-powered software capabilities. In addition analyses using saliva, urine, and blood instead of biopsied tissue make for more patient-friendly test systems.
- “The Majors” – the top IVD companies participating in multiple IVD markets
- “The Participants”– Molecular diagnostic companies that are by now established in the market
- “The Stars”- Those companies that have shown better than average results
- “Newcomers”– Companies that have novel or interesting approaches to keep an eye on
- “High Potentials”– Companies that could show explosive growth but also could fall based on market developments
- “Specialists” in various areas (microbiology, histology, quality control, sample prep)
- New Platforms Making Their Mark based on Miniaturization and Biochips
- The Growing Significance of Quality Control Products and Innovations in this area
- The Sequence Begins: Innovations in DNA Sequencing, Key Players and its Future in Clinical Medicine
- Pharmacodiagnostics and Where it Stands in 2011
- The Latest Growth Numbers of LDTs, regulatory activity, and their impact on the Market
- The $1000 Genome – If and When
- Miniaturization and Multiplexing
- The Ongoing Saga of Patents
- Healthcare Reform and Reimbursement Trends
- Integrated Sample Preparation and System Automation – A Growing Number of Competitors
- Developments in Mass Spectroscopy
- Screening for Wellness: the Latest on Consumer Tests
Market size and forecasts in the report are for manufacturer’s revenues. Secondary and primary resources, including: trade publications, annual report and interviews with key executives in molecular diagnostics were used for this study.
All Kalorama reports advertise the single user price. Use is limited to one user. We also feature department and global pricing for reports that we be utilized by more than one user at your company. Please consult ask your sales representative or select the correct license on our website.
For Kalorama’s take on the healthcare news of the week, based on our analysis of healthcare markets, follow Kalorama Information’s Key Point Blog at http://kaloramakeypoint.blogspot.com/